Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kaohsiung J Med Sci. 2021 Apr;37(4):262-267. doi: 10.1002/kjm2.12364. Epub 2021 Jan 27.
Over the past decades, marked advancement has been made in the prevention and treatment of hepatitis B virus (HBV) infection. Due to highly effective antiviral therapies for chronic hepatitis B (CHB), long-term clinical outcomes in patients with CHB has also been dramatically improved. However, current antiviral therapies for CHB cannot completely abolish the risk of hepatocellular carcinoma (HCC). In addition, current treatment guidelines for CHB should be interpreted with caution given that HBV-associated hepatocarcinogenesis could be underway in patients who are not eligible for antiviral therapies by current guidelines. Therefore, efforts to reconcile treatment guidelines with recent clinical evidence should be made for reducing further development of HCC. In this article, we review the secondary prevention of HBV-related HCC with current antiviral therapies.
在过去的几十年中，乙型肝炎病毒 (HBV) 感染的预防和治疗取得了显著进展。由于慢性乙型肝炎 (CHB) 的高效抗病毒治疗，CHB 患者的长期临床结局也得到了显著改善。然而，目前用于 CHB 的抗病毒治疗并不能完全消除肝细胞癌 (HCC) 的风险。此外，鉴于目前的指南不适用于不符合抗病毒治疗条件的患者，因此，对于 CHB 的治疗指南应谨慎解读。因此，应努力使治疗指南与最近的临床证据相协调，以减少 HCC 的进一步发展。在本文中，我们回顾了目前抗病毒治疗对 HBV 相关 HCC 的二级预防。
